Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

Table 2 Meta-comparisons of bevacizumab with interferon (Bev + IFN), sunitinib (Sun), pazopanib (Pazo), and interferon alone (IFN) as first-line therapy for patients with clear cell renal cell carcinoma

Comparison	Overall survival	Progression-free survival	Response
	HR (95% CI; 95% PI)	HR (95% CI; 95% PI)	OR (95% CI; 95% PI)
Bev + IFN vs IFN	0.86 (0.76-0.97; 0.76-0.97)	0.66 (0.57-0.77; 0.55-0.81)	2.65 (1.94-3.61; 1.89-3.71)
Sun vs IFN	0.82 (0.67-1.00; 0.67-1.00)	0.54 (0.43-0.67; 0.42-0.69)	6.33 (4.27-9.37; 4.17-9.59)
Pazo vs IFN	0.74 (0.57-0.97; 0.57-0.97)	0.56 (0.42-0.76; 0.41-0.78)	8.51 (5.20-13.93; 5.10-14.19)
Sun vs Bev + IFN	0.95 (0.75-1.20; 0.75-1.20)	0.81 (0.62-1.06; 0.61-1.09)	2.39 (1.45-3.94; 1.42-4.01)
Pazo vs Bev + IFN	0.86 (0.64-1.16; 0.64-1.16)	0.85 (0.61-1.19; 0.60-1.21)	3.21 (1.79-5.75; 1.77-5.84)
Pazo vs Sun	0.91 (0.76-1.08; 0.76-1.08)	1.05 (0.86-1.28; 0.83-1.33)	1.35 (1.00-1.81; 0.97-1.86)

ISSN: 1471-2407